Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.5glegtPn.js ...

The deal will give Zimmer Biomet access to Paragon's surgical implants and equipment used to treat foot and ankle ailments, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.4, a ...

Fintel reports that on January 29, 2025, Needham downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst ...

Fintel reports that on January 29, 2025, Canaccord Genuity downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst Price Forecast Suggests 12.55% Upside As of January 29, 2025, ...

Paragon 28, Inc. (NYSE:FNA) shares are trading higher premarket on Wednesday. On Tuesday, the company inked a deal to be ...

William Blair has recently reduced Paragon 28 Inc (FNA) stock to Mkt Perform rating, as announced on Today, according to Finviz. Earlier, on Today, Needham had reduced the stock from a Buy to Hold.

Stephens downgraded Paragon 28 (FNA) to Equal Weight from Overweight with a $13 price target after Zimmer Biomet (ZBH) agreed to acquire the ...

NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business, with a $1.1 billion deal to acquire the ...

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...

Paragon 28 shares rose 8.4% after Zimmer Biomet Holdings agreed to acquire the company. Shares were trading around $13.02. The stock is up about 2.6% over the last year.